Tag: virus

OTTAWA, ON, Oct. 19, 2026 /CNW/ -- In partnership with provincial and territorial public health officials, the Public Health Agency of Canada (PHAC) announced today...

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®...

BEIJING, Oct. 15, 2026 /PRNewswire/ -- From September 21 to 24, a workshop on Green Control Technology for Corn Pests and Diseases in the...

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across...

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely...

Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in houseSALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq:...

Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC.Roche will...

Independent initiative will fund research focused on practical vineyard solutionsNAPA VALLEY, Calif. , Oct. 6, 2026 /PRNewswire/ -- Winegrowers and wineries have pledged $2.5...

The new CSL Seqirus-developed vaccine will be introduced to the annual influenza vaccination programme from next year (2027/28).Its introduction marks a significant advance in...

Glycoengineered CHO technology expands Kemp's ability to control protein development, characterization, and productionFREDERICK, Md., Sept. 17, 2026 /PRNewswire/ -- Kemp Proteins, LLC is expanding...

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety...

SandboxAQ will use physics-based AI to develop, validate, and then commercialize critical formulations for American semiconductor manufacturing and to drive national security needsPALO ALTO,...